Funded in part by Pfizer, GlaxoSmithKline, Novartis Pharmaceuticals Corporation
Dietary magnesium intake and fracture risk: data from a large prospective study
Veronese N, Stubbs B, Solmi M, Noale M, Vaona A, Demurtas J, Maggi S
The British journal of nutrition · 47 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Cohort study (indexed by PubMed)
- Studied in
- People
- Main outcome
- Clinical events such as disease or death
Who paid for it
- Funding
- Industry funded
- Nonprofit
- Foundation for the National Institutes of Health
- Government
- U.S. Department of Health and Human Services
- Company
- Pfizer
- Company
- GlaxoSmithKline
- Company
- Novartis Pharmaceuticals Corporation
- Government
- National Institutes of Health
- Government
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Government
- NIAMS NIH HHS
- Grants
- U.S. Department of Health and Human Services (N01-AR-2-2258); U.S. Department of Health and Human Services (N01-AR-2-2261); U.S. Department of Health and Human Services (N01-AR-2-2262); Pfizer (N01-AR-2-2258); National Institute of Arthritis and Musculoskeletal and Skin Diseases (N01 AR022262); Pfizer (N01-AR-2-2259); GlaxoSmithKline (N01‐AR‐2‐2261); Foundation for the National Institutes of Health ((N01-AR-2-2258); National Institutes of Health (N01 AR‐2‐2260); National Institutes of Health (N01-AR-2-2258,N01-AR-2-2259,N01-AR-2-2260,N01-AR-2-2261,N01-AR-2-2262); National Institute of Arthritis and Musculoskeletal and Skin Diseases (N01 AR022260); Novartis Pharmaceuticals Corporation (N01-AR-2-2261); Novartis Pharmaceuticals Corporation (N01-AR-2-2262); GlaxoSmithKline (N01-AR-2-2258); GlaxoSmithKline (N01-AR-2-2260); National Institutes of Health (N01-AR-2-2258); National Institute of Arthritis and Musculoskeletal and Skin Diseases (N01 AR022261); National Institute of Arthritis and Musculoskeletal and Skin Diseases (N01 AR022259); National Institute of Arthritis and Musculoskeletal and Skin Diseases (N01 AR022258); GlaxoSmithKline (N01-AR-2-2259); Pfizer (N01-AR-2-2260); Novartis Pharmaceuticals Corporation (N01-AR-2-2260); U.S. Department of Health and Human Services (N01-AR-2-2259); National Institutes of Health (N01‐AR‐2‐2259); U.S. Department of Health and Human Services (N01-AR-2-2260); National Institutes of Health (N01-AR-2-2261); Novartis Pharmaceuticals Corporation (N01-AR-2-2258); Pfizer (N01-AR-2-2261); Novartis Pharmaceuticals Corporation (N01-AR-2-2259); Pfizer (N01-AR-2-2262); GlaxoSmithKline (N01-AR-2-2262); National Institutes of Health (N01-AR-2-2262)
Based on 8 listed funder(s).
Publication
- Published
- 2017-06-14 · Br J Nutr · vol. 117 · issue 11 · pp. 1570–1576
- Publisher
- Cambridge University Press
- Cited
- 69 citations · more than 95% of similar papers · 4.2× the field average
- Impact
- Top 10% most cited in its field
- References
- 38 works
- Access
- Free to read
- Research areas
- Magnesium in Health and Disease · Bone health and osteoporosis research · Bone Metabolism and Diseases
- Keywords
- Medicine, Osteoarthritis, Osteoporosis, Confounding, Hazard ratio, Prospective cohort study, Cohort study, Lower risk, Cohort, Internal medicine, Confidence interval
- MeSH
- humans, osteoporosis, osteoarthritis, knee, magnesium, micronutrients, diet, diet surveys, nutrition assessment, incidence, proportional hazards models, risk factors, follow-up studies, prospective studies, sex factors, dietary supplements, aged, middle aged, female, male, osteoporotic fractures
7 authors
From IT, GB
- Nicola Veronese · correspondingNeuroscience Institute; National Research Council
- Brendon StubbsKing's College London; South London and Maudsley NHS Foundation Trust
- Marco SolmiUniversity of Padua
- Marianna NoaleNeuroscience Institute; National Research Council
- Alberto VaonaUniversity of Verona; Azienda Ospedaliera Universitaria Integrata Verona
- Jacopo DemurtasAzienda Usl Toscana Centro
Abstract
Research considering the relationship between dietary Mg and osteoporosis as well as fractures are sparse and conflicting. We therefore aimed to investigate Mg intake and the onset of fractures in a large cohort of American men and women involved in the Osteoarthritis Initiative over a follow-up period of 8 years. Dietary Mg intake (including that derived from supplementation) was evaluated through a FFQ at baseline and categorised using sex-specific quintiles (Q); osteoporotic fractures were evaluated through self-reported history. Overall, 3765 participants (1577 men; 2071 women) with a mean age of 60·6 (sd 9·1) years were included. During follow-up, 560 individuals (198 men and 368 women) developed a new fracture. After adjusting for fourteen potential confounders at baseline and taking those with lower Mg intake as reference (Q1), men (hazard ratio (HR) 0·47; 95 % CI 0·21, 1·00, P=0·05) and women (HR 0·38; 95 % CI 0·17, 0·82, P=0·01) in the highest quintile reported a significantly lower risk for fracture. Women meeting the recommended Mg intake were at a 27 % decreased risk for future fractures. In conclusion, higher dietary Mg intake has a protective effect on future osteoporotic fractures, especially in women with a high risk for knee osteoarthritis. Those women meeting the recommended Mg intake appear to be at a lower risk for fractures.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.